Trial Information
A Randomized, Double-Blind, Placebo-Controlled Trial of Tomivosertib in Combination with Anti-PD-(L)1 Therapy in Subjects with Non-Small Cell Lung Cancer as First-Line Therapy or When Progressing on Single-Agent First-Line Anti-PD-(L)1 Therapy
Sponsor: eFFECTOR Therapeutics Medpace
Contact us regarding Clinical Trials at MOHRSCH@usoncology.com
or call us at
877-664-7724
